Extended treatment of Abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis

we valuated the efficacy and safety of the selective JAK1 inhibitor Abrocitinib in the treatment of chronic actinic dermatitis patients for the first time. And propose to use the Clinical Active Score of Chronic Actinic Dermatitis（CAS-CAD）score to assess the disease severity of chronic actinic dermatitis. At the same time, we analyzed the changes of inflammatory protein levels before and after the treatment through the inflammation panel of Olink Proteomics Analysis, providing valuable insights for future research on the mechanism of CAD.